Detailed Mechanism Funding and Narrative

Years of mechanism: 2013 2014 2015 2016 2017 2018

Details for Mechanism ID: 17037
Country/Region: South Africa
Year: 2015
Main Partner: University of the Witwatersrand
Main Partner Program: Wits Reproductive Health and HIV Institute
Organizational Type: NGO
Funding Agency: USAID
Total Funding: $247,741 Additional Pipeline Funding: $6,211,600

NOTE: PEPFAR no longer creates activity narratives for each mechanism. In their place, PEPFAR has begun releasing mechanism specific targets that reveal the achievements and programs that are expected of the funding. If available for this mechanism, these targets are presented below.

Mechanism Allocation by Budget Code for Selected Year
Care: Adult Care and Support (HBHC) $0
Care: TB/HIV (HVTB) $0
Care: Pediatric Care and Support (PDCS) $0
Health Systems Strengthening (OHSS) $0
Biomedical Prevention: Prevention of Mother to Child Transmission (MTCT) $0
Treatment: Adult Treatment (HTXS) $247,741
Treatment: Pediatric Treatment (PDTX) $0
Mechanism Target Information

Since COP2014, PEPFAR no longer produces narratives for every mechanism it funds. However, PEPFAR has now included performance targets or indicator information for each mechanism based on the Monitoring, Evaluation, and Reporting (MER) system. The MER guidance is available on PEPFAR's website https://www.pepfar.gov/reports/guidance/. Note that COP years 2014-2015 were under a previous version of the MER system and the indicators and definitions may have changed as of the new 2.0 guidance.

MER Indicator MER description Target Fiscal Year Target
HRH_PRE By Graduates: Doctors 2016 150
HRH_PRE By Graduates: Nurses 2016 200
HRH_PRE Number of new HCW who graduated from a pre-service training institution or program as a result of PEPFAR-supported strengthening efforts, within the reporting period, by select cadre 2016 350
HRH_PRE Sum of Graduates disaggregates 2016 350
PMTCT_ARV Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry) 2016 5,767
PMTCT_ARV Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry) 2016 638
PMTCT_ARV Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery 2016 5,652
PMTCT_ARV Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery 2016 625
PMTCT_EID Number of infants who had a virologic HIV test within 12 months of birth during the reporting period 2016 613
PMTCT_STAT Number of new ANC and L&D clients 2016 25,220
PMTCT_STAT Number of new ANC and L&D clients 2016 2,836
PMTCT_STAT Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) 2016 25,220
PMTCT_STAT Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) 2016 2,836
TB_ART The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period 2016 1,649
TB_ART The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period 2016 1,319
TX_CURR Aggregated Age/Sex: 15+ Female 2016 61,229
TX_CURR Aggregated Age/Sex: 15+ Male 2016 40,821
TX_CURR Number of adults and children receiving antiretroviral therapy (ART) 2016 108,338
TX_CURR Sum of Aggregated Age/Sex 15+ 2016 102,050
TX_CURR Sum of Aggregated Age/Sex disaggregates 2016 102,050
TX_NEW Aggregated Grouping by Age/Sex: 15+ Female 2016 4,270
TX_NEW Aggregated Grouping by Age/Sex: 15+ Male 2016 2,846
TX_NEW Number of adults and children newly enrolled on antiretroviral therapy (ART) 2016 7,490
TX_NEW Sum of Aggregated Age/Sex disaggregates 2016 7,116